Clinical Trials Logo

Intravenous Drug Usage clinical trials

View clinical trials related to Intravenous Drug Usage.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04432233 Recruiting - Clinical trials for Helicobacter Pylori Infection

Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease

Start date: June 15, 2020
Phase: Phase 4
Study type: Interventional

Helicobacter pylori infection causes active peptic ulcer disease and related complications like bleeding and pyloric obstruction. Usually, clinicians tended to treat Helicobacter pylori infection after active peptic ulcer disease and related complicaitons getting healed, which spent time and money. This study is designed to evaluate the efficacy and safety of intravenous administration of metronidazole, levofloxacin and esomeprazole triple therapy in the treatment of Helicobacter pylori infection combined with peptic ulcer disease related complications.

NCT ID: NCT03981445 Recruiting - Opioid Use Clinical Trials

Integrated HIV Prevention and HCV Care for PWID

M2HepPrEP
Start date: November 14, 2019
Phase: N/A
Study type: Interventional

The objective of this study is to compare and evaluate two strategies of delivering PrEP and Hepatitis C Virus (HCV) treatment to people who inject drugs to determine the best method of providing care. Participants will be randomized to one of two treatment arms: on-site integrated care or off-site referral to specialized care.

NCT ID: NCT02999217 Recruiting - Clinical trials for Colorectal Neoplasms

Intravenous Iron for Correction of Anaemia After Colorectal Surgery

Start date: October 2016
Phase: Phase 4
Study type: Interventional

This 4-week prospective double blind anaemia management study evaluates the effect of high-dose postoperative intravenous iron vs placebo for patients after colorectal cancer surgery. Patients with preoperative levels of haemoglobin 90-120 g/l will be randomly assigned to receive either 1 g of intravenous iron or equal amount of saline postoperatively. Comparison will be based on the levels of haemoglobin, ferritin and other haematological parameters over time and profile of clinical recovery. The primary end point is that iron isomaltoside given postoperatively is superior to placebo in terms of increase and stability of levels of haemoglobin and other haematological parameters.